Keyphrases
ACVR1
8%
Best Available Therapy
16%
IL-1 Receptor-associated Kinase 1 (IRAK1)
8%
Inhibitor Study
8%
Janus Kinase 2 (JAK2)
8%
Janus Kinase Inhibitors
8%
Myelofibrosis
100%
Non-responders
16%
Overall Survival
100%
Overall Survival Benefit
16%
Pacritinib
100%
Platelet Count
16%
Platelets
8%
Retrospective Analysis
8%
Ruxolitinib
33%
Spleen Volume
100%
Survival Analysis
100%
Survival Benefit
8%
Survival Curve
8%
Thrombocytopenia
16%
Trial Registration
8%
Twice Daily
8%
Volume Reduction
100%
Medicine and Dentistry
Janus Kinase
14%
Janus Kinase Inhibitor
14%
Myelofibrosis
100%
Overall Survival
100%
Pacritinib
100%
Platelet
42%
Ruxolitinib
57%
Thrombocytopenia
28%
Nursing and Health Professions
Janus Kinase
14%
Janus Kinase Inhibitor
14%
Myelofibrosis
100%
Overall Survival
100%
Pacritinib
100%
Platelet Count
28%
Ruxolitinib
57%
Thrombocytopenia
28%
Pharmacology, Toxicology and Pharmaceutical Science
Janus Kinase
14%
Janus Kinase Inhibitor
14%
Myelofibrosis
100%
Overall Survival
100%
Pacritinib
100%
Ruxolitinib
57%
Thrombocytopenia
28%
Biochemistry, Genetics and Molecular Biology
ACVR1
14%
IRAK1
14%
Janus Kinase
14%
Janus Kinase Inhibitor
14%
Overall Survival
100%
Platelet
14%
Platelet Count
28%
Ruxolitinib
57%
Thrombocytopenia
28%